NeuroX1 is developing a target ID and drug discovery platform leveraging proprietary generative AI algorithms to create the next generation of therapeutics for neurological disorders. Our early-stage pipeline consists of several pre-clinical assets partnered with a variety of pharma companies and institutions.
-
所属行业
-
生物技术研究
-
规模
-
2-10 人
-
总部
-
Austin,TX
-
类型
-
私人持股
-
创立
-
2021
-
领域
-
generative drug discovery、biotechnology、neurology、neurodegenerative、rare disease、pediatric rare disease、AI、neuroscience、cancer、brain、generativeAI、Alzheimer's、Parkinson's、preclinical、MS、big pharma、partnerships、target ID、generative drugs、novel drugs、novel small molecules、future of drug discovery、inhibitors、neurosurgery、neural networks、platform technology、drug discovery platform、computational chemistry、computational biology和target discovery